{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:43:23Z","timestamp":1778856203688,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Journal"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.bj.2022.04.003","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T18:13:28Z","timestamp":1650478408000},"page":"100532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prognosis of chronic kidney disease in patients with non-alcoholic fatty liver disease: a Northeastern Taiwan community medicine research cohort"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2932-6878","authenticated-orcid":false,"given":"Ting-Shuo","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-Wen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Lang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chiau","family":"Shyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuen-Chan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7656-4695","authenticated-orcid":false,"given":"Rong-Nan","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bj.2022.04.003_bib1","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.bj.2022.04.003_bib2","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/hep.31173","article-title":"Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD","volume":"72","author":"Paik","year":"2020","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.bj.2022.04.003_bib3","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/apt.15673","article-title":"Modelling NAFLD disease burden in four Asian regions-2019-2030","volume":"51","author":"Estes","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bj.2022.04.003_bib4","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","article-title":"NAFLD as a driver of chronic kidney disease","volume":"72","author":"Byrne","year":"2020","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.bj.2022.04.003_bib5","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jhep.2017.08.024","article-title":"Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: a cohort study","volume":"67","author":"Sinn","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.bj.2022.04.003_bib6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","article-title":"Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis","volume":"79","author":"Mantovani","year":"2018","journal-title":"Metabolism"},{"issue":"10225","key":"10.1016\/j.bj.2022.04.003_bib7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bj.2022.04.003_bib8","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.30254","article-title":"Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"issue":"1 Pt 1","key":"10.1016\/j.bj.2022.04.003_bib9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jfma.2019.03.016","article-title":"A community-based study on the application of fatty liver index in screening subjects with nonalcoholic fatty liver disease","volume":"119","author":"Chen","year":"2020","journal-title":"J Formos Med Assoc"},{"issue":"10","key":"10.1016\/j.bj.2022.04.003_bib10","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/apt.12963","article-title":"Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease","volume":"40","author":"Fedchuk","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bj.2022.04.003_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"10.1016\/j.bj.2022.04.003_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ki.2013.444","article-title":"Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward","volume":"85","author":"Levin","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.bj.2022.04.003_bib13","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/ki.2013.243","article-title":"Comments on KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"84","author":"Andrassy","year":"2013","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.bj.2022.04.003_bib14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1467-789X.2005.00175.x","article-title":"Prevalence of obesity in Taiwan","volume":"6","author":"Chu","year":"2005","journal-title":"Obes Rev"},{"issue":"17","key":"10.1016\/j.bj.2022.04.003_bib15","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American heart association\/national heart, lung, and blood institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.bj.2022.04.003_bib16","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.2337\/diacare.21.12.2191","article-title":"Correct homeostasis model assessment (HOMA) evaluation uses the computer program","volume":"21","author":"Levy","year":"1998","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.bj.2022.04.003_bib17","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.bj.2022.04.003_bib18","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.bj.2022.04.003_bib19","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1053\/j.ajkd.2010.02.337","article-title":"Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions","volume":"55","author":"Levey","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.bj.2022.04.003_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v038.i08","article-title":"Multi-state models for Panel data: the msm package for R. 2011","volume":"38","author":"Jackson","year":"2011","journal-title":"J Stat Softw"},{"issue":"11","key":"10.1016\/j.bj.2022.04.003_bib21","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/sim.3812","article-title":"Multi-state Markov models for disease progression in the presence of informative examination times: an application to hepatitis C","volume":"29","author":"Sweeting","year":"2010","journal-title":"Stat Med"},{"issue":"18","key":"10.1016\/j.bj.2022.04.003_bib22","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1002\/sim.4780141804","article-title":"Multi-state models and diabetic retinopathy","volume":"14","author":"Marshall","year":"1995","journal-title":"Stat Med"},{"key":"10.1016\/j.bj.2022.04.003_bib23","series-title":"Causal inference: what if","author":"Hern\u00e1n","year":"2020"},{"key":"10.1016\/j.bj.2022.04.003_bib24","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/EDE.0b013e318225c2be","article-title":"DAGitty: a graphical tool for analyzing causal diagrams","volume":"22","author":"Textor","year":"2011","journal-title":"Epidemiology"},{"issue":"5","key":"10.1016\/j.bj.2022.04.003_bib25","article-title":"An introduction to causal inference","volume":"6","author":"Pearl","year":"2010","journal-title":"Int J Biostat"},{"issue":"2","key":"10.1016\/j.bj.2022.04.003_bib26","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/apt.13860","article-title":"Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis","volume":"45","author":"Vilar-Gomez","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.bj.2022.04.003_bib27","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.bj.2022.04.003_bib28","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1161\/HYPERTENSIONAHA.117.09508","article-title":"Temporal relationship between hyperuricemia and insulin resistance and its impact on future risk of hypertension","volume":"70","author":"Han","year":"2017","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.bj.2022.04.003_bib29","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/HYPERTENSIONAHA.117.09685","article-title":"Chicken or the egg? Hyperuricemia, insulin resistance, and hypertension","volume":"70","author":"Dawson","year":"2017","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.bj.2022.04.003_bib30","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41366-018-0074-5","article-title":"Temporal relationship between hyperuricemia and obesity, and its association with future risk of type 2 diabetes","volume":"42","author":"Han","year":"2018","journal-title":"Int J Obes(Lond)"},{"issue":"9","key":"10.1016\/j.bj.2022.04.003_bib31","first-page":"2749","article-title":"Roles of hyperuricemia in metabolic syndrome and cardiac-kidney-vascular system diseases","volume":"10","author":"Wang","year":"2018","journal-title":"Am J Transl Res"},{"issue":"6","key":"10.1016\/j.bj.2022.04.003_bib32","first-page":"1887","article-title":"Robust causal inference using directed acyclic graphs: the R package \u2018dagitty\u2019","volume":"45","author":"Textor","year":"2016","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.bj.2022.04.003_bib33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2369-15-45","article-title":"Regression methods for investigating risk factors of chronic kidney disease outcomes: the state of the art","volume":"15","author":"Boucquemont","year":"2014","journal-title":"BMC Nephrol"},{"issue":"3","key":"10.1016\/j.bj.2022.04.003_bib34","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/hep.21334","article-title":"FIB-4: a simple, inexpensive and accurate marker of fibrosis in HCV-infected patients","volume":"44","author":"Vallet-Pichard","year":"2006","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.bj.2022.04.003_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180951","article-title":"The fatty liver index as a predictor of incident chronic kidney disease in a 10-year prospective cohort study","volume":"12","author":"Huh","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.bj.2022.04.003_bib36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","article-title":"Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers","volume":"68","author":"Vilar-Gomez","year":"2018","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.bj.2022.04.003_bib37","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.bj.2022.04.003_bib38","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/gut.2010.216077","article-title":"Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease","volume":"59","author":"McPherson","year":"2010","journal-title":"Gut"}],"container-title":["Biomedical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417022000580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417022000580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:13:38Z","timestamp":1762420418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2319417022000580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2319417022000580"],"URL":"https:\/\/doi.org\/10.1016\/j.bj.2022.04.003","relation":{},"ISSN":["2319-4170"],"issn-type":[{"value":"2319-4170","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognosis of chronic kidney disease in patients with non-alcoholic fatty liver disease: a Northeastern Taiwan community medicine research cohort","name":"articletitle","label":"Article Title"},{"value":"Biomedical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bj.2022.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V. on behalf of Chang Gung University.","name":"copyright","label":"Copyright"}],"article-number":"100532"}}